Fibromyalgia Treatment Market to Reach $1,414.4 Mn by 2027; Heavy Demand for Antiepileptic Drugs to Foster Growth

The global fibromyalgia treatment market size is expected to reach USD 1,414.4 million by 2027. The increasing government initiatives for fibromyalgia is expected to favor healthy growth of the market, mentioned in a report, titled “Fibromyalgia Treatment Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Antidepressants, Antiepileptic, Muscle Relaxants, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Forecast, 2020-2027.” The market size stood at USD 1,918.1 million in 2019 and is expected to exhibit a CAGR of 9.2% between 2020 and 2027.

Clinical-trial of NYX-2925 by Aptinyx to Support Market

Aptinyx, a clinical-stage biopharmaceutical company, announced the Phase II study of NYX-2925 for treating patients with painful diabetic peripheral neuropathy (DPN). NYX-2925 is a novel oral NMDA receptor modulator, which will be used to treat chronic pain. In clinical studies, NYX-2925 exhibited activity that affects central pain processing, resulting in the mitigation of pain and other symptoms linked to chronic pain conditions. According to the American Chronic Pain Association (2017), an estimated 2 to 4 percent of Americans have fibromyalgia. Besides, pharmaceutical companies' increasing focus on innovative drugs will have a tremendous effect on the fibromyalgia treatment market growth.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/fibromyalgia-treatment-market-105016

Rising Cases of Fibromyalgia to Propel Market

The increasing cases of fibromyalgia are expected to spur lucrative opportunities for the market in the forthcoming years. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), approximately five million individuals aged 18 years or over in the U.S. have fibromyalgia. Additionally, over 80 to 90% of fibromyalgia patients are females. Furthermore, the increasing government initiatives for fibromyalgia treatment is likely to aid the expansion of the market. For instance, the European League Against Rheumatism (EULAR) issued a recommendation in their 2016 guidelines against using non-steroidal anti-inflammatory drugs (NSAID) to treat fibromyalgia. Besides, the increasing awareness coupled with favorable guidelines will consequently boost the market in the foreseeable future.

Focus on Mergers and Acquisitions by Industry Players to Reinforce Industry

The global market is dominated by major prominent companies such as Pfizer, Inc., Eli Lilly and Company, and Allergan. The key players are focused on mergers, acquisitions, innovative product launches to consolidate their position in the market. Moreover, companies such as Tonix Pharmaceuticals, Aptinyx, Teva Pharmaceutical Industries Ltd., Novartis AG, Sun Pharmaceuticals, Astellas Pharma are also adopting strategies to strengthen their position in the industry.

The Report Lists the Key Players in this Market:

• Pfizer, Inc. (U.S.)


• Eli Lilly and Company (U.S)


• Allergan (Ireland)


• Tonix Pharmaceuticals (U.S)


• Aptinyx (U.S)


• Teva Pharmaceutical Industries Ltd. (Israel)


• Novartis AG (Switzerland)


• Sun Pharmaceuticals (India)


• Astellas Pharma Inc (Japan)


• Other Prominent Players

Further Report Findings:

• Regional Analysis:  The market size in North America stood at USD 1,253.5 million in 2019 and is expected to remain dominant during the forecast period. The growth is attributable to the rising prevalence of fibromyalgia and higher adoption of advanced approved products to manage the disease.


• Leading Segment: The antiepileptic is expected to account for the lion’s fibromyalgia treatment market share during the forecast period. Lyrica is an antiepileptic drug used in the management of fibromyalgia among the population.

The Market is Segmented into: